Skip to main content
James List, MD, Endocrinology, Princeton, NJ

JamesFrankListMD

Endocrinology • Princeton, NJ

Diabetes, Lipid Metabolism

Physician

Join to view full profile

Dr. List is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. List's full profile

Already have an account?

Education & Training

  • Massachusetts General Hospital
    Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2000 - 2003
  • Brigham and Women's Hospital/Children's Hospital/Harvard Medical School
    Brigham and Women's Hospital/Children's Hospital/Harvard Medical SchoolResidency, Internal Medicine/Pediatrics, 1996 - 2000
  • University of Minnesota Medical School
    University of Minnesota Medical SchoolClass of 1996

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2013 - 2025
  • MA State Medical License
    MA State Medical License 1998 - 2025
  • TX State Medical License
    TX State Medical License 2003 - 2008

Publications & Presentations

PubMed

Journal Articles

  • New Clinical Trial Designs for Establishing Drug Efficacy and Safety in a Precision Medicine Era  
    James List, MD, Diabetes, Obesity and Metabolism

Press Mentions

  • Late-Breaking Phase 3 a DUE Data Show Investigational Single-Tablet Combination Therapy of Macitentan and Tadalafil Significantly Improves Pulmonary Haemodynamics Versus Monotherapy in Patients with Pulmonary Arterial Hypertension (PAH)
    Late-Breaking Phase 3 a DUE Data Show Investigational Single-Tablet Combination Therapy of Macitentan and Tadalafil Significantly Improves Pulmonary Haemodynamics Versus Monotherapy in Patients with Pulmonary Arterial Hypertension (PAH)March 6th, 2023
  • Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting
    Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual MeetingOctober 1st, 2022
  • Johnson & Johnson : The Janssen Pharmaceutical - New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO (Rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
    Johnson & Johnson : The Janssen Pharmaceutical - New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO (Rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related EventsSeptember 30th, 2021
  • Join now to see all

Dr. James List, Dr. James List, MD, Dr. J List, Dr. James Frank List